Furthermore, several novel therapeutic modalities, including diverse inhibitors of the phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway (PAM pathway), poly ADP‐ribose polymerase (PARP) inhibitors, antibody‐drug conjugates (ADCs) and proteolysis‐targeting chimaera (PROTAC) protein degraders, help to provide additional clinical benefits for patients with BC [26, 27, 28, 29, 30, 31, 32]. The gene discussed is AKT1; the disease is breast cancer.